Statement of Changes in Beneficial Ownership (4)

FORM 4

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number:

3235-0287

Estimated average burden
hours per response...

0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * INGENITO GARY	2. Issuer Name and Ticker or Trading Symbol CATALYST PHARMACEUTICALS, INC. [ CPRX ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) Chief Medical Officer
(Last)          (First)          (Middle) 355 ALHAMBRA CIRCLE, SUITE 1250	3. Date of Earliest Transaction (MM/DD/YYYY) 12/4/2019
(Street) CORAL GABLES, FL 33134 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock, par value $0.001 per share	12/4/2019		M		150000	A	$2.53	150000	D
Common stock, par value $0.001 per share	12/5/2019		S		150000 (1)	D	$4.821	0	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to purchase common stock	$2.53	12/4/2019		M		150000		(2)	12/30/2022	Common Stock	150000	$0	886000	D

Explanation of Responses:
(1)	Dr. Ingenito has advised the Company that this sale of shares was to complete the raising of funds required for the purchase of a home by a family member and does not relate to any disagreements with the Company on any matter relating to the Company's operations, policies and practices. Dr. Ingenito remains an officer of the Company.
(2)	The option was granted on December 30, 2015 and previously vested in two equal annual installments.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
INGENITO GARY 355 ALHAMBRA CIRCLE, SUITE 1250 CORAL GABLES, FL 33134			Chief Medical Officer

Signatures
/s/ Gary Ingenito		12/6/2019
**Signature of Reporting Person		Date